Price To Earnings Ratio 80.52 | Sector PE 67.58 |
PB Ratio 9.46 | Sector PB 8.81 |
EPS 24.95 | Dividend Yield 0.23 |
Today's Volume 99.339 K | 5 Day Avg. Volume 220.891 K |
PEG Ratio -7.62 | Market Cap. ₹ 10,850.00 Cr. |
Time | METROPOLIS | VS | Industry |
---|---|---|---|
1 Day | -0.01% | 1.52% | |
1 Week | -2.36% | -1.38% | |
1 Month | -8.08% | 0.56% | |
6 Months | 1.41% | 14.63% | |
1 Year | 20.44% | 39.1% |
Period (Days) | SMA | Indication |
---|---|---|
10 | 2122.96 | Bearish |
20 | 2132.94 | Bearish |
30 | 2171.85 | Bearish |
50 | 2172 | Bearish |
100 | 2115.36 | Bearish |
200 | 1945.26 | Bullish |
Annual | FY 2024 | FY 2023 | FY 2022 | ||||
---|---|---|---|---|---|---|---|
Operating Activities | 264.07 | 247.09 | 253.27 | ||||
Investing Activities | -89.41 | 46.79 | -737.57 | ||||
Financing Activities | -181.20 | -292.33 | 162.52 | ||||
Net Cash Flow | -6.54 | 1.56 | -321.78 |
All Figures in ₹ Cr., unless mentioned otherwise
Name | 1D (%) | 1W (%) | 1M (%) | 6M (%) | 1Y (%) |
---|---|---|---|---|---|
Metropolis Healthcare | -0.01 | -2.36 | -8.08 | 1.41 | 20.44 |
Aarti Drugs | 0.3 | -4.96 | -7.06 | 3.53 | 4.5 |
Abbott India | -0.59 | -1.45 | -4.84 | 0.09 | 16.69 |
Advanced Enzyme Tech | 1.41 | -22.43 | -25.25 | -4.97 | 17.9 |
Ajanta Pharmaceuticals | 1.43 | -2.7 | -14.64 | 8.27 | 45.89 |
Metropolis Healthcare Limited is an Indian diagnostics company operating through the pathology services segment. The company offers a variety of clinical laboratory tests and profiles used for disease prediction, early detection, diagnostic screening, confirmation and monitoring. The company also provides analytical and support services to clinical research organisations for their clinical research projects. Its services include pathology testing services, corporate wellness, hospital laboratory and clinical research services. The company offers a variety of tests and profiles, which include advanced tests to diagnose cancer, neurological disorders, infectious diseases and various genetic abnormalities. It owns a chain of diagnostic centres in India, South Asia, Africa and the Middle East. The company has spread its footprint across 20 Indian states and over 210 cities.